First-in-class drugs for chronic pulmonary disorders

Respivert developed a pipeline of novel, narrow spectrum, kinase inhibitors, that possessed a unique anti-inflammatory profile, and which were being developed as first-in-class treatments for moderate to severe asthma, COPD and cystic fibrosis.